Conrad A (1,2,3), Boccard M (1,2,3), Valour F (1,2,3), Alcazer V (3,4), Tovar Sanchez AT (5,6), Chidiac C (1,3), Laurent F (1,2,3,7), Vanhems P (2,3,5,6), Salles G (3,4), Brengel-Pesce K (8), Meunier B (8,9), Trouillet-Assant S (2,3,8,10), Ader F (1,2,3); Lyon HEMINF Study Group + Collaborators (38):
Immune reconstitution after haematopoietic stem cell transplantation (HSCT) is a complex and dynamic process, varying from a state of nearly complete immunosuppression to an expected full immune recovery. Specific vaccination guidelines recommend reimmunisation after HSCT but data regarding vaccine efficacy in this unique population are scarce. New immune functional assays could enable prediction of vaccine response in the setting of HSCT.
METHODS and ANALYSIS:
A prospective, longitudinal single-centre cohort study of autologous and allogeneic HSCT recipients was designed in order to determine the vaccine response to five vaccine targets (pneumococcus, hepatitis B virus, Haemophilus Influenzae type b, tetanus and diphtheria) and to correlate it to immune function parameters. A workflow was set up to study serological response to vaccines and to describe the functional immune status of 100 HSCT recipients (50 autologous and 50 allogeneic) before and 3, 12 and 24 months after primary immunisation. At each time point, ‘basic’ immune status recording (serology, immunophenotyping of lymphocyte subsets by flow cytometry) will be assessed. The immune response will furthermore be evaluated before and 3 months after primary vaccination by two ex vivo immune functional assays assessing: (1) tumour necrosis factor alpha, interferon gamma production and host messenger RNA expression on whole-blood stimulation by lipopolysaccharide or Staphylococcus aureus enterotoxin B and (2) T-lymphocyte proliferation in response to a standard mitogen (phytohaemagglutinin) or to selected recall antigens. Reference intervals will be determined from a cohort of 30 healthy volunteers. This translational study will provide data describing vaccine response, immune functionality of HSCT recipients over time and will allow mapping HSCT recipients with regard to their immune function.
ETHICS AND DISSEMINATION:
Ethical approval has been obtained from the institutional review board (no 69HCL17_0769). Results will be communicated at scientific meetings and submitted for publication in peer-reviewed journals.
TRIAL REGISTRATION NUMBER:
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ
Author information :
1 : Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.
2 : CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, Lyon, France.
3 : Université Claude Bernard Lyon I, Lyon, France.
4 : Département d’Hématologie Clinique, Hospices Civils de Lyon, Lyon, France.
5 : Service d’Hygiène, Epidémiologie, Infectiovigilance et Prévention, Hospices Civils de Lyon, Lyon, France.
6 : Équipe Épidémiologie et Santé Internationale, Laboratoire des Pathogènes Émergents, Fondation Mérieux, Centre International de Recherche en Infectiologie, Inserm U1111, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5308, Ecole Nationale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon, France.
7 : Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
8 : Joint Research Unit, Hospices Civils de Lyon/BioMerieux, Lyon, France.
9 : Soladis, Lyon, France.
10 : Virpath, Inserm U1111, Lyon, France.